As Bristol-Myers, Pfizer battle copycat challengers in court, FDA approves generics for blockbuster Eliquis
Eliquis, the blockbuster blood thinner that has been a leading fixture in Bristol-Myers’ top line for years, now has FDA approved copycats.
Sold by an alliance between Bristol and Pfizer, the drug has generated at least a billion dollars in annual sales since 2014 and has kept growing: In the first nine months of 2019, it raked in nearly $5.9 billion in sales, surpassing the $5.4 billion generated by Bristol’s pioneering checkpoint inhibitor Opdivo.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
